Literature DB >> 25797557

Putting patients at the heart of health-care research.

Melanie Calvert1, Derek Kyte2, Maria von Hildebrand3, Madeleine King4, David Moher5.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25797557     DOI： 10.1016/S0140-6736(15)60599-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols.

Authors:  Rebecca Mercieca-Bebber; Michael Friedlander; Peey-Sei Kok; Melanie Calvert; Derek Kyte; Martin Stockler; Madeleine T King
Journal:  Qual Life Res       Date:  2016-06-13       Impact factor: 4.147

Review 2.  SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.

Authors:  Melanie Calvert; Madeleine King; Rebecca Mercieca-Bebber; Olalekan Aiyegbusi; Derek Kyte; Anita Slade; An-Wen Chan; E Basch; Jill Bell; Antonia Bennett; Vishal Bhatnagar; Jane Blazeby; Andrew Bottomley; Julia Brown; Michael Brundage; Lisa Campbell; Joseph C Cappelleri; Heather Draper; Amylou C Dueck; Carolyn Ells; Lori Frank; Robert M Golub; Ingolf Griebsch; Kirstie Haywood; Amanda Hunn; Bellinda King-Kallimanis; Laura Martin; Sandra Mitchell; Thomas Morel; Linda Nelson; Josephine Norquist; Daniel O'Connor; Michael Palmer; Donald Patrick; Gary Price; Antoine Regnault; Ameeta Retzer; Dennis Revicki; Jane Scott; Richard Stephens; Grace Turner; Antonia Valakas; Galina Velikova; Maria von Hildebrand; Anita Walker; Lari Wenzel
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 2.692

3.  IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.

Authors:  Eduard Shantsila; Ronnie Haynes; Melanie Calvert; James Fisher; Paulus Kirchhof; Paramjit S Gill; Gregory Y H Lip
Journal:  BMJ Open       Date:  2016-10-05       Impact factor: 2.692

4.  Management of Patient-Reported Outcome (PRO) Alerts in Clinical Trials: A Cross Sectional Survey.

Authors:  Derek Kyte; Jonathan Ives; Heather Draper; Melanie Calvert
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

Review 5.  Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes-An ESDO Report.

Authors:  Eric Van Cutsem; Aimery De Gramont; Geoffrey Henning; Philippe Rougier; Franck Bonnetain; Thomas Seufferlein
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

Review 6.  Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review.

Authors:  Rebecca Mercieca-Bebber; Michael J Palmer; Michael Brundage; Melanie Calvert; Martin R Stockler; Madeleine T King
Journal:  BMJ Open       Date:  2016-06-15       Impact factor: 2.692

7.  Current practices in patient-reported outcome (PRO) data collection in clinical trials: a cross-sectional survey of UK trial staff and management.

Authors:  Derek Kyte; Jonathan Ives; Heather Draper; Melanie Calvert
Journal:  BMJ Open       Date:  2016-10-03       Impact factor: 2.692

8.  A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.

Authors:  Dipak Kotecha; Melanie Calvert; Jonathan J Deeks; Michael Griffith; Paulus Kirchhof; Gregory Yh Lip; Samir Mehta; Gemma Slinn; Mary Stanbury; Richard P Steeds; Jonathan N Townend
Journal:  BMJ Open       Date:  2017-07-20       Impact factor: 2.692

9.  A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice.

Authors:  Rebecca Mercieca-Bebber; Michael Friedlander; Melanie Calvert; Martin Stockler; Derek Kyte; Peey-Sei Kok; Madeleine T King
Journal:  J Patient Rep Outcomes       Date:  2017-10-04

10.  The FOsmetpantotenate Replacement Therapy (FORT) randomized, double-blind, Placebo-controlled pivotal trial: Study design and development methodology of a novel primary efficacy outcome in patients with pantothenate kinase-associated neurodegeneration.

Authors:  Thomas Klopstock; Maria L Escolar; Randall D Marshall; Belen Perez-Dueñas; Sarah Tuller; Aleksandar Videnovic; Feriandas Greblikas
Journal:  Clin Trials       Date:  2019-05-06       Impact factor: 2.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.